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11. INTRODUCTION
PHARMACEUTICAL ANALYSIS1
Pharmaceutical analysis1 plays a vital role in the pharmaceutical product development. 
Pharmaceutical analysis is a specialized branch of analytical chemistry. Analytical chemistry 
involves separating, identifying, and determining the relative amounts of components in a sample 
matrix. 
Pharmaceutical analysis derives its principles from various branches of sciences like physics, 
microbiology, nuclear science, and electronics etc. Qualitative analysis reveals the chemical 
identity of the sample. Quantitative analysis establishes the relative amount of one or more of these 
species or analytes in numerical terms. Qualitative analysis is required before a quantitative 
analysis can be undertaken. 
A separation step is usually a necessary part of both a qualitative and quantitative analysis. The 
results of typical quantitative analysis can be computed from two measurements. One is the mass or 
volume of sample to be analyzed and second is the measurement of some quantity that is 
proportional to the amount of analyte in that sample and normally completes the analysis. 
Instruments play a key role in the quantitative analysis of pharmaceutical chemistry.
INSTRUMENTAL METHODS OF ANALYSIS
Instrumental methods are exciting and fascinating part of chemical analysis that interacts with all 
areas of chemistry and with many other areas of pure and applied sciences. Analytical 
instrumentation plays an important role in the production and evaluation of new products and in the 
protection of consumers and environment. 
This instrumentation provides lower detection limits required to assure safe foods, drugs, water and 
air. Instrumental methods are widely used by Analytical chemists to save time, to avoid chemical 
separation and to obtain increased accuracy. Most instrumental techniques fit into one of the four-
principle areas mentioned below.
a) Spectrophotometric techniques
 UV and Visible Spectrophotometry
 Fluorescence and Phosphorescence Spectrophotometry
2 Atomic Spectrophotometry (Emission &Absorption)
 Infrared Spectrophotometry
 Raman Spectrophotometry
 X-Ray Spectrophotometry
 Nuclear Magnetic Resonance Spectroscopy
 Mass Spectroscopy  
 Electron spin Resonance Spectroscopy
b) Electrochemical Techniques                                                                                                                                                                                                                             
 Potentiometry
 Voltametry
 Electrogravimetry
 Conductometry
 Amperometry
c) Chromatographic Techniques
 High Performance Liquid Chromatography 
 Gas chromatography 
 High Performance Thin Layer Chromatography 
 Thin Layer Chromatography 
 GC- MS (Gas chromatography - Mass Spectroscopy
 LC-MS (Liquid Chromatography - Mass Spectroscopy
d) Miscellaneous techniques
 Thermal analysis
 Kinetic techniques
Chromatographic techniques are predominantly used in the pharmaceutical industry for a large 
variety of samples. HPLC is one of the chromatographic techniques is widely used for checking the 
purity of new drug candidates, monitoring changes or scale ups of synthetic procedures, evaluating 
new formulations, and scrutinizing quality control/assurance of final drug products.
31.1 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY2
High performance liquid chromatography2 is basically a highly improved form of column 
chromatography. Instead of a solvent being allowed to drip through a column under gravity, it is 
forced through under high pressures of up to 400 atmospheres, that makes it much faster. It also 
allows using a very much smaller particle size for the column packing material which gives a much 
greater surface area for interactions between the stationary phase and the molecules flowing past it. 
This allows a much better separation of the components of the mixture. The other major 
improvement over column chromatography concerns the detection methods which can be used. 
These methods are highly automated and extremely sensitive.
HPLC employs a liquid mobile phase and a very finely divided stationary phase. In order to obtain 
satisfactory flow rate, liquid must be pressurized to a few thousands of pounds per square inch. The 
rate of distribution of drugs between stationary and mobile phase is controlled by diffusion process. 
If diffusion is minimized, a faster and effective separation can be achieved. The technique of high 
performance liquid chromatography is so called because of its improved performance when 
compared to classical column chromatography. Advances in column technology, high-pressure 
pumping system and sensitive detectors have transformed liquid column chromatography into high 
speed, efficient, accurate and highly resolved method of separation.
The HPLC is the method of choice in the field of analytical chemistry, since this method is specific, 
robust, linear, precise and accurate and the limit of detection is low and also it offers the following 
advantages.
 Speed (many analysis can be accomplished in 20 min or less)
 Greater sensitivity (various detectors can be employed)
 Improved resolution (wide variety of stationary phases)
 Reusable columns (expensive columns but can be used for many analysis)
 Ideal for the substances of low viscosity
 Easy sample recovery, handling and maintenance.
 Instrumentation leads itself to automation and quantification (less time and less labor)
 Precise and reproducible
 Integrator itself does calculations.
4SEPARATION PRINCIPLES OF HPLC
Adsorption chromatography employs high-surface area particles that adsorb the solute molecules. 
Usually a polar solid such as a silica gel, alumina or porous glass beads and a non-polar mobile 
phase such as heptane, octane or chloroform are used in adsorption chromatography. 
In adsorption chromatography, adsorption process is described by competition model and solvent 
interaction model. Competition model assumes that entire surface of the stationary phase is covered 
by mobile phase molecules as result of competition for adsorption site. In solvent interaction model 
the retention results from the interaction of solute molecule with the second layer of adsorbed 
mobile phase molecules. The differences in affinity of solutes for the surface of the stationary phase 
account for the separation achieved.    
In partition chromatography, the solid support is coated with a liquid stationary phase. The relative 
distribution of solutes between the two liquid phases determines the separation. The stationary 
phase can either be polar or non polar. If the stationary phase is polar and the mobile phase is non 
polar, it is called normal phase partition chromatography. If the opposite case holds, it is called 
reverse-phase partition chromatography. In normal phase mode, the polar molecule partition 
preferentially in to the stationary phase and are retained longer than non-polar compounds. In 
reverse phase partition chromatography, the opposite behaviour is observed.
TYPES OF HPLC TECHNIQUES
Based on modes of chromatography:
 Normal phase chromatography
 Reverse phase chromatography
Based on principle of separation:
 Adsorption chromatography
 Ion exchange chromatography
 Size exclusion chromatography
 Affinity chromatography 
5 Chiral phase chromatography
Base on elution technique:
 Isocratic separation 
 Gradient separation
Based on the scale of operation:
 Analytical HPLC 
 Preparative HPLC
REVERSED PHASE CHROMATOGRAPHY3
In 1960s, chromatographers started modifying the polar nature of the silanol group by chemically 
reacting silicon with organic silanes. The object was to make silica less polar or non-polar so that 
polar solvents can be used to separate water-soluble polar compounds. Since the ionic nature of the 
chemically modified silica in now reversed i.e., it is non-polar or the nature of the phase is reverted, 
the chromatographic separation carried out with such silica is referred to as reverse-phase 
chromatography.
Reverse phase liquid chromatography (RPLC) is considered as the method of choice for the 
analysis of pharmaceutical compounds for several reasons, such as its compatibility with aqueous 
and organic solutions as well as with different detection systems and its high consistency and 
repeatability. Sensitive and accurate RPLC analysis, whether in the pharmaceutical or bioanalytical 
field, necessitates the use of stationary phases which give symmetrical and efficient peaks. 
Therefore, manufacturers of stationary phases are continuously improving and introducing new 
RPLC products, and the selection of various types of reverse phase stationary phases is high. The 
needs for consistency as well as the globalization of the pharmaceutical companies require that the 
methods will be transferred from site to site, using either the same column brands or their 
equivalents. Therefore, an extensive categorization or characterization of the rich selection of 
stationary phases has been done in recent years.
6The stationary phase in the Reverse Phase chromatographic columns is a hydrophobic support that 
is consisted mainly of porous particles of silica gel in various shapes (spherical or irregular) at 
various diameters (1.8, 3, 5, 7, 10 µm etc.) at various pore sizes (such as 60, 100, 120, 300).
The surface of these particles is covered with various chemical entities, such as various 
hydrocarbons (C1, C6, C4, C8, C18, etc). In most methods C18 columns are used currently to 
separate medicinal materials, which sometimes are called ODS (octedecylsilane) or RP-18. A polar 
solvent is used as mobile phase.
The parameters that govern the retention in Reversed Phase systems are the following:
A. The chemical nature of the stationary phase surface. 
B. The type of solvents that compose the mobile phase
C.    pH and ionic strength of the mobile phase
A. The chemical nature of the stationary phase
The chemical nature is determined by the size and chemistry of hydrocarbon bonded on the silica 
gel surface, its bonding density (units of µmole/m2), and the purity and quality of the silica gel 
support. As a rule, the more carbons in a bonded hydrocarbon the more it retains organic solutes 
(as long as similar % coverage is compared). The higher the bonding density the longer the organic 
solutes are retained. A column is considered relatively hydrophobic if its bonding density exceeds 
3 µmole/m2.
Very important modifiers of the stationary phase's surface are surface-active substances used as 
mobile phase's additives, acting as ion-pair reagents. These are substances such as tri-ethylamine or 
tetrabutylamine or hexyl, heptyl, octyl sulfonate. They are distributed between the mobile phase 
and the hydrophobic surface and cover it with either positive (alkylamines) or negative (alkyl
sulfonates) charges. This change of the surface into charged surface affects the retention 
significantly, especially on charged species in the sample.
B. Composition of the mobile phase 
As a rule, the weakest solvent in Reverse Phase is the most polar one, water. The other polar 
organic solvents are considered stronger solvents, where the order of solvent strength follows more 
7or less their dielectric properties, or polarity. The less polar the solvent added to the mobile phase, 
the stronger it gets, shortening the retention times.
C. PH and ionic strength of the mobile phase
When the samples contain solutes of ionizable functional groups, such as amines, carboxyls, 
phosphates, phosphonates, sulfates and sulfonates, it is possible to control their ionization degree 
with the help of buffers in the mobile phase. As a rule, the change of an ionizable molecule to an 
ion makes it more polar and less available to the stationary phase.
NORMAL PHASE CHROMATOGRAPHY 
In normal phase chromatography, the stationary phase is polar adsorbent. The mobile phase is 
generally a mixture of non-aqueous solvents. The silica structure is saturated with silanol group at 
the end in normal phase separations. These OH groups are statistically distributed over the whole of 
the surface. The silanol groups represent the active sites (very polar) in the stationary phase. 
This forms a weak bond with many molecules in the vicinity when any of the following 
interactions are present. Dipole-induced dipole, dipole-dipole, hydrogen bonding, -complex 
bonding. These situations arise when the molecule has one or several atoms with lone pair electrons 
or a double bond. The adsorption strengths and hence ‘K’ value (elution series) increase in the 
following order. Saturated hydrocarbon < olefins < aromatic < organic < halogen compounds < 
sulphides < ethers < esters < aldehydes and ketones < amines < sulphones < amides < carboxylic 
acids. The strength of interactions depends not only on the functional groups in the sample 
molecule but also on stearic factors. If a molecule has several functional groups, then the most polar 
one determines the reaction properties.
Chemically modified silica, such as aminopropyl, cyanopropyl and diol phases are the stationary 
phases alternative to silica gel in normal phase chromatography.
The aminopropyl and cyanopropyl phases provide opportunities for specific interactions between 
the analyte and the stationary phase and thus offer additional options for the optimization of 
separations. Other advantages of bonded phases lie in the increased homogeneity of the stationary 
phase surface. Polar modifiers such as acetic acid or triethylamine (TEA) are added to the mobile 
phase, to deactivate the more polar adsorption sites on the surface of stationary phase, which in turn 
will improve peak shape as well as the reproducibility of the retention times. 
8ADSORPTION CHROMATOGRAPHY
The stationary phase is an adsorbent (like silica gel or any other silica based packing) and the 
separation is based on repeated adsorption-desorption steps.
ION EXCHANGE CHROMATOGRAPHY
Separation is based on the charge-bearing functional groups, anion exchange for sample negative 
ion, or cation exchange - for sample positive ion. Gradient elution by pH is common. 
AFFINITY CHROMATOGRAPHY
Separation is based on a chemical interaction specific to the target species. The more popular 
reverse phase mode uses a buffer and an added counter-ion of opposite charge to the sample with 
separation being influenced by pH, ionic strength, temperature, concentration of and type of organic 
co-solvent(s). Affinity chromatography, common for macromolecules, employs a ligand 
(biologically active molecule bonded covalently to the solid matrix) which interacts with its 
homologous antigen (analyte) as a reversible complex that can be eluted by changing buffer 
conditions.
CHIRAL CHROMATOGRAPHY:
Separation of the enantiomers can be achieved on chiral stationary phases by formation of 
diastereomers via derivatizing agents or mobile phase additives on a chiral stationary phase. When 
used as an impurity test method, the sensitivity is enhanced if the enantiomeric impurity elutes 
before the enantiomeric drug.
ISOCRATIC SEPARATION
In this technique, the same mobile phase combination is used throughout the process of separation. 
The same polarity or elution strength is maintained the process.
GRADIENT SEPARATION     In this 
technique, a mobile phase combination of lower polarity or elution strength is used followed by 
gradually increasing the polarity or elution strength.
9ANALYTICAL HPLC        
    In this only analysis of the samples are done. Recovery of the samples for reusing is normally not 
done, since the samples used are very low.
PREPARATIVE HPLC
   Where analysis of the individual fractions of pure compounds can be collected using fraction 
collector. The collected samples are reused.
ION-PAIR CHROMATOGRAPHY11
Ion Pair Chromatography (IPC) is used to separate ionic analytes on a 
Column. An Ion Pair reagent is added to modulate retention of the ionic analytes. Ion-pair 
chromatography is commonly used in combination with UV detection, in which case it is referred 
as reverse phase ion-pair chromatography (RPIPC).
Principle of ion-pairing:
With the aid of ion pair chromatography it is possible to separate the same analytes as in ion 
exclusion chromatography, but the separation mechanism is completely different. The stationary 
phases used are completely polar reverse phase materials such as are used in distribution 
chromatography. A so-called ion pair regent is added to the eluents; this consists of anionic or 
cationic surfactants such as tetra alkyl ammonium salts or n-alkylsulfonic acids. Together with the 
oppositely charged analyte ions the ion pair reagents form an uncharged ion pair, which can be 
retarded at the stationary phase by hydrophobic interactions. Separation is possible because of the 
formation constants of the ion pairs and their different degrees of adsorption. Figure 1 shows a 
simplified static ion exchange model in which it is assumed that interactions with the analytes only 
occur after adsorption of the ion pair reagent at the stationary phase.
Separation mechanism:
Ion-exchange selectivity is mediated by
selectivity of an ion-pair separation is determined primarily by the mobile phase. The two major 
components of aqueous mobile phase are the ion
concentration of each component can be varied to achieve desired separation. The ion
is a large ionic molecule that carries a charge opposite to analyte of interest. It usually has both 
hydrophobic region to interact with the analyte. Stationa
hydrophobic resins such as polystyrene, divinyl benzene or bonded silica. A single stationary phase 
can be used for either anion or cation analysis.
Although the retention mechanism of ion
theories have been proposed:
 Ion pair formation
 Dynamic ion exchange
 Ion interaction
In first model, the analyte and ion
the mobile phase and stationary 
organic solvent in the mobile phase as in reverse phase chromatography. 
The dynamic ion-exchange model maintains that the hydrophobic portion of ion
adsorbs to the hydrophobic stationary phase to form a dynamic ion
Fig No.1: Ion Pairing
both the mobile phase and stationary phase. In contrast the 
-pair reagent and the organic solvent; the type and 
ry phases used for ion
-pair chromatography is not fully understood, three major 
-pair reagent form a neutral pair, which is then partitions between 
phase. Retention can be controlled by varying the concentration of 
-exchange surface. The analyte 
10
-pair reagent 
-pair are neutral, 
-pair reagent 
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is retained on this surface, as it would in classic Ion Chromatography. Using this scenario, solvents 
used in the mobile phase can be used to impede interaction of ion-pair reagent with the stationary 
phase, there by altering the capacity of the column.
A third model describes an electrical double layer that is formed when ion-pair reagent permeates 
the stationary phase, carrying with it an associated counter-ion. Retention of analyte ion in this 
model is dependent upon a combination of factors including those described in first two models.
Typical IP reagents are divided into two categories
 Cationic: These are used for anion analysis. Cationic ion-pair reagents include ammonium 
and tetra methyl-, tetraethyl-, tetra propyl-, and tetra butyl ammonium.
 Anionic: These reagents used for cation analysis. Anionic ion-pair reagents include 
hydrochloric, perchloric, and perfluorocarboxylic acids and pentane-, hexane-, heptane-, and 
octane sulfonic acids.
INSTRUMENTATION OF HPLC4
The individual components HPLC and their working functions are described below. 
 Mobile phase and reservoir
 Solvent degassing system
 Pump
 Injector
 Column
 Detector
 Data system                
                               
MOBILE PHASE AND RESERVOIR
The most common type of solvent reservoir is a glass bottle. Most of the manufacturers supply 
these bottles with special caps, Teflon tubing and filters to connect to the pump inlet and to the 
purge gas (helium) used to remove dissolved air. 
The mobile phase is pumped under pressure from one or several reservoirs and flows through the 
column at a constant rate. With micro particulate packing, there is a high
chromatography column. Eluting power of the mobile phase is determined by it
the polarity of the stationary phase and the nature of the sample components. For normal phase 
separations, eluting power increases with increasing polarity of the solvent but for reversed phase 
separations, eluting power decreases with
conditions can be achieved by making use of mixture of two solvents. Some other properties of the 
solvents, which need to be considered for a 
detector compatibility, flammability and toxicity.
Mobile phases used for HPLC typically are mixtures of organic solvents and water or aqueous 
buffers. Isocratic methods are preferable to gradient methods. Gradient methods will sometimes be 
required when the molecules being separated have vastly different partitioning properties. When a 
gradient elution method is used, care must be taken to ensure that all solvents are miscible. 
The following points should also be considered when choosing a mobile phase
Fig No.2: Block diagram of HPLC
-pressure drop across a 
increasing solvent polarity. Optimum separating 
successful separation, are boiling point, viscosity, 
12
s overall polarity, 
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It is essential to establish that the drug is stable in the mobile phase for at least the duration of the 
analysis.
Excessive salt concentrations should be avoided. High salt concentrations can result in 
precipitation, which can damage HPLC equipment.
The mobile phase should have a pH 2.5 and pH 7.0 to maximize the lifetime of the column.
Reduce cost and toxicity of the mobile phase by using methanol instead of acetonitrile when 
possible minimize the absorbance of buffer. Since trifluoroacetic acid, acetic acid or formic acid 
absorb at shorter wavelengths, they may prevent detection of products without chromophores above 
220 nm. Carboxylic acid modifiers can be frequently replaced by phosphoric acid, which does not 
absorb above 200 nm.
Use volatile mobile phases when possible, to facilitate collection of products and LC-MS analysis. 
Volatile mobile phases include ammonium acetate, ammonium phosphate, formic acid, acetic acid, 
and trifluoroacetic acid. Some caution is needed as these buffers absorb below 220 nm.
Ionizable compounds in some cases can present some problems when analyzed by reverse phase 
chromatography. Two modifications of the mobile phase can be useful in reverse phase HPLC for 
ionizable compounds. One is called ion suppression and other ion pairing chromatography. In both 
techniques, a buffer is used to ensure that the pH of the solution is constant and usually at least 1.5 
pH units from a pKa of the drug to ensure that one form predominates. 
If pH is approximately equal to pKa, peak broadening can occur. In ion suppression 
chromatography, the pH of the aqueous portion of the mobile phase is adjusted to allow the neutral 
form of the drug to predominate. This ensures that the drug is persistent in only one form and 
results in improvement of the peak shape and consistency of retention times. 
In ion pairing chromatography, the pH of the mobile phase is adjusted so that the drug is 
completely ionized. If necessary to improve peak shape or lengthen retention time, an alkyl sulfonic 
acid salt or bulky anion such as trifluoroacetic acid is added to the ion pair to cationic drugs or a 
quaternary alkyl ammonium salt is added to ion-pair to anionic drugs. Ion pairing chromatography 
also allows the simultaneous analysis of both neutral and charged compounds.
SOLVENT DEGASSING SYSTEM12
The constituents of the mobile phase should be degassed and filtered before use. Several methods 
are employed to remove the dissolved gases in the mobile phase. 
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They include heating and stirring, vacuum degassing with an aspirator, filtration through 0.45 filter, 
vacuum degassing with an air-soluble membrane, helium purging ultra signification or purging or 
combination of these methods. Helium purging and storage of the solvent under helium is not 
sufficient for degassing aqueous solvents. It is useful to apply a vacuum for 5-10 min and then keep 
the solvent under a helium atmosphere. 
HPLC systems are also provided an online degassing system, which continuously removes the 
dissolved gases from the mobile phase.
PUMP:
High pressure pumps are needed to force solvents through packed stationary phase beds. Smaller 
bed particles require higher pressures. There are many advantages to using smaller particles, but 
they may not be essential for all separations. 
The most important advantages are: higher resolution, faster analyses, and increased sample load 
capacity. However, only the most demanding separations require these advances in significant 
amounts. 
Many separation problems can be resolved with larger particle pickings that require less pressure. 
Flow rate stability is another important pump feature that distinguishes pumps. Very stable flow 
rates are usually not essential for analytical chromatography.
However, if the user plans to use a system in size exclusion mode, then there must be a pump which 
provides an extremely stable flow rate. An additional feature found on the more elaborate pumps is 
external electronic control. Although it adds to the expense of the pump, external electronic control 
is a very desirable feature when automation or electronically controlled gradients are to be run. 
Alternatively, this becomes an undesirable feature (since it is an unnecessary expense) when using 
isocratic methods. The degree of flow control also varies with pump expense. More expensive 
pumps include such state of-the-art technology as electronic feedback and multi headed 
configurations. 
It is desirable to have an integrated degassing system, either helium purging, or membrane filtering.
INJECTOR
Sample introduction can be accomplished in various ways. The simplest method is to use an 
injection valve. 
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In more sophisticated LC systems, automatic sampling devices are incorporated where the sample 
is introduced with the help of auto samplers and microprocessors. In liquid chromatography, liquid 
samples may be injected directly and solid samples need only be dissolved in an appropriate 
solvent. 
The solvent need not be the mobile phase, but frequently it is judiciously chosen to avoid detector 
interference, column/component interference, and loss in efficiency or all of these.
It is always best to remove particles from the sample by filtering over a 5 μm filter, or centrifuging, 
since continuous injections of particulate material will eventually cause blockages in injection 
devices or columns. Sample sizes may vary widely. 
The availability of highly sensitive detectors frequently allows use of the small samples which yield 
the highest column performance. Sample introduction techniques can be used with a syringe or an 
injection valve.
COLUMN
The heart of the system is the column. The choice of common packing material and mobile phases 
depends on the physical properties of the drug. 
Many different reverse phase columns will provide excellent specificity for any particular 
separation. It is therefore best to routinely attempt separations with a standard C8 or C18 column and 
determine if it provides good separations. If this column does not provide good separation or the 
mobile phase is unsatisfactory, alternate methods or columns should be explored. 
Reverse phase columns differ by the carbon chain length, degree of end capping and percent carbon 
loading. Diol, cyano and amino groups can also be used for reverse phase chromatography.
Typical HPLC columns are 5, 10, 15 and 25 cm in length and are filled with small diameter (3, 5 or 
10 μm) particles. The internal diameter of the columns is usually 4.6 mm; this is considered the best 
compromise for sample capacity, mobile phase consumption, speed and resolution. However, if 
pure substances are to be collected (preparative scale), then larger diameter columns may be 
needed. Packing the column tubing with small diameter particles requires high skill and specialized 
equipment. 
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For this reason, it is generally recommended that all but the most experienced chromatographers 
purchase prepacked columns, since it is difficult to match the high performance of professionally 
packed LC columns without a large investment in time and equipment.
In general, LC columns are fairly durable and one can expect a long service life unless they are 
used in some manner which is intrinsically destructive, as for example, with highly acidic or basic 
eluents, or with continual injections of 'dirty' biological or crude samples.
It is wise to inject some test mixture (under fixed conditions) into a column when new, and to 
retain the chromatogram. If questionable results are obtained later, the test mixture can be injected 
again under specified conditions.
The two chromatograms may be compared to establish whether or not the column is still useful.
DETECTOR
Today, optical detectors are used most frequently in liquid chromatographic systems. These 
detectors pass a beam of light through the flowing column effluent as it passes through a low 
Volume (~ 10μl) flow cell. 
The variations in light intensity caused by UV absorption, fluorescence emission or change in 
refractive index, from the sample components passing through the cell, are monitored as changes in 
the output voltage. 
These voltage changes are recorded on a strip chart recorder and frequently are fed into a computer 
to provide retention time and peak area data. The most commonly used detector in LC is the 
ultraviolet absorption detector. 
A variable wavelength detector of this type, capable of monitoring from 190 to 400 nm, will be 
found suitable for the detection of the majority samples. 
Other detectors in common use include: Photo Diode Array UV detector (PDA), refractive index 
(RI), fluorescence (FLU), electrochemical (EC). 
The RI detector is universal but also the less sensitive one. FLU and EC detectors are quite 
sensitive (up to 10-15 pmole) but also quite selective.
DATA SYSTEM
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Since the detector signal is electronic, using modern data collection techniques can aid the signal 
analysis. In addition, some systems can store data in a retrievable form for highly sophisticated 
computer analysis at a later time. 
The main goal in using electronic data systems is to increase analysis accuracy and precision, while 
reducing operator attention. 
There are several types of data systems, each differing in terms of available features. In routine 
analysis, where no automation (in terms of data management or process control) is needed, a pre-
programmed computing integrator may be sufficient. 
If higher control levels are desired, a more intelligent device is necessary, such as a data station or 
minicomputer. The advantages of intelligent processors in chromatographs are found in several 
areas. 
First, additional automation options become easier to implement. Secondly, complex data analysis
becomes more feasible. These analysis options include such features as run parameter optimization 
and deconvolution (i.e. resolution) of overlapping peaks. 
Finally, software safeguards can be designed to reduce accidental misuse of the system.
HPLC THEORY5,6:
System Suitability Parameters
High performance liquid chromatography is defined as a separation of mixtures of compounds due 
to differences in their distribution equilibrium between two phases, the stationary phase packed 
inside columns and the mobile phase, delivered through the columns by high pressure pumps.
Components whose distribution into the stationary phase is higher, are retained longer, and get 
separated from those with lower distribution into the stationary phase. The theoretical and practical 
foundations of this method were laid down at the end of 1960s and at the beginning of 1970s.
The theory of chromatography has been used as the basis for System- Suitability tests, which are set 
of quantitative criteria that test the suitability of the chromatographic system to identify and 
quantify drug related samples by HPLC at any step of the pharmaceutical analysis.
18
Retention Time (tR), Capacity Factor k' & Relative Retention Time (RRT)
The time elapsed between the injection of the sample components into the column and their 
detection is known as the Retention Time (tR).
The retention time is longer when the solute has higher affinity to the stationary phase due to its 
chemical nature. For example, in reverse phase chromatography, the more lypophilic compounds 
are retained longer.
Therefore, the retention time is a property of the analyte that can be used for its identification. A 
non retained substance passes through the column at a time t0, called the Void Time.
Retention factor is calculated as follows:
The Capacity Factor describes the thermodynamic basis of the separation and its definition is the 
ratio of the amounts of the solute at the stationary and mobile phases within the analyte band inside 
the chromatographic column:
Where Cs is the concentration of the solute at the stationary phase and Cm is its concentration at the 
mobile phase and phi is the ratio of the stationary and mobile phase volumes all within the 
chromatographic band. 
The Retention Factor is used to compare the retention of a solute between two chromatographic 
systems, normalizing it to the column's geometry and system flow rate.
The retention factor value should be in between 1-20. The need to determine the void time can be 
tricky sometimes, due to the instability of the elution time of the void time marker, t0, therefore, 
when the chromatogram is complex in nature, and one known component is always present at a 
certain retention time, it can be used as a retention marker for other peaks. In such cases the ratio 
between the retention time of any peak in the chromatogram and the retention time of the marker is 
used (tR (Peak) / tR (Marker)) and referred to as the 
RRT is also used instead of the capacity rati
compare its extent of retention in two different chromatographic systems. 
The sharpness of a peak relative to its retention time is a measure of the system's efficiency, 
calculated as N, plate count. Band
molecular diffusion, and mass-transfer kinetics and extra
the separation. 
The sharpness of a peak is relevant to the limit of detection and limit of qu
chromatographic system. The sharper the peak for a specific area, the better is its signal
hence the system is capable of detecting lower concentrations.
Therefore, the efficiency of the chromatographic system must be establ
suitability test before the analysis of low concentrations that requires high sensitivity of the system, 
such as the analysis of drug impurities and degradation products.
Efficiency: Plate Count N and Peak Capacity P
The efficiency of the separation is determined by the Plate Count N when working at isocratic 
conditions, whereas it is usually measured by Peak Capacity P
conditions.
The following equation for the plate count is used by the United States Pharmac
calculate N:
Where w is measured from the baseline peak width calculated using lines tangent to the peak width 
at 50 % height. European and Japanese Pharmacopoeias use the peak width at 50% of the peak 
height, hence the equation becomes:
Relative Retention Time (RRT).
o for the identification of the analyte as well as to 
-broadening phenomena in the column such as eddy diffusion, 
-column effects reduce the efficiency of 
ished by the system 
c
c when working at gradient 
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antification of the 
-to-noise; 
opoeia (USP) to 
Peak Capacity Pc is defined as number of peaks that can be separated within a retention window for 
a specific pre-determined resolution. In other words, it is the runtime measured in peak width units 
(34). It is assumed that peaks occur over the gradie
Therefore, Peak Capacity can be calculated from the peak widths 
follows:
Where n is the number of peaks at the segment of the gradient selected for the calculation, 
peak capacity can be simply the gradient run time div
the peaks the higher is the peak capacity, hence the system should be able to resolve more peaks at 
the selected run time as well as detect lower concentrations.
Another measure of the column's chromatographic 
Theoretical Plate (HETP) which is calculated from the following equation:
HETP = (L/N)
Where L is column length and N is the plate count.
The behavior of HETP as function of linear velocity has been described by various equations. It is 
frequently called "The Van-Deemter curve", and it is frequently used to describe and characterize 
various chromatographic stationary phases' performance and 
The lower are the values of HETP, the more efficient is the chromatographic system, enabling the 
detection of lower concentrations due to the enhanced signal
chromatogram.
Peak Asymmetry Factor Af and
The chromatographic peak is assumed to have a Gaussian shape under ideal conditions, describing 
normal distribution of the velocity of the molecules populating the peak zone migrating through the 
stationary phase inside the column.
nt chromatogram. 
w in the chromatogram as 
ided by the average peak width.
efficiency is the Height Equivalent to 
HETP is measured in micrometer.
compare them to each other. 
-to-noise ratio of all the peaks in the 
Tailing Factor T
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tg. Thus 
The sharper 
Any deviation from the normal distribution indicates non
migration process therefore might jeopardize the integrity of the peak's integration, redu
accuracy of the quantification.
always measured in the system suitability step of the analysis.
The deviation from symmetry is measured by the 
calculation of Asymmetry Factor
Where A and B are sections in the horizontal line parallel to the baseline, drawn at 10% of the peak 
height 
The calculation of Tailing Factor
suggested by the pharmacopeias, is described by the following equation:
Where A and B are sections in the horizontal line parallel to the baseline, drawn at 5% of the peak 
height. The USP suggests that 
precise and accurate quantitative measurement.
Selectivity Factor: Alfa and Resolution Factor Rs
The separation is a function of the thermodynamics of the system. Substances are separated in a 
chromatographic column when their rate of 
between the stationary and mobile phases.
The Selectivity Factor, α, and Resolution Factor, Rs
adjacent peaks. The Selectivity Factor
the two peaks (k'2/k'1), whereas the 
retention times of the two peaks relative to their width
The equation that describes the experimental measurement 
follows:
-ideality of the distribution and the 
This is the reason why USP Tailing is a peak's parameter almost 
Asymmetry Factor, Af or Tailing Factor
, Af is described by the following equation:
, T, which is more widely used in the pharmaceutical industry, as 
Tailing Factor should be in the range of 0.5 up to 
migration differs, due to their different distribution 
, measure the extent of separation between two 
accounts only for the ratio of the Retention Factors
Resolution Factor, Rs, accounts for the difference between the 
of the Resolution Factor, Rs
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cing the 
T. The 
2 to assure a 
, k', of 
, is as 
Where tR is the retention time of peaks 1 and 2 respectively and 
the tangents' baseline. According to the pharmacopeias 
quantitative measurement.
The resolution is a critical value when working with complex samples such as drug impurities and 
degradation products, or when the formulation is complex and excipients might interfere with the 
quantitative measurements. Therefore, it is a
stage before the quantitative work of these types of samples.
The sample used for the measurements of 
Resolution Solution, It usually contains the components that are the most difficult to resolve. 
The theoretical description of the 
some of the above parameters, the plate count 
capacity factors k': 
It can be clearly seen from this equation that the plate count is the most effecting parameter in the 
increase of the chromatographic resolution.
particle diameter, it explains the reduction in particle diameter of the stationary phase material 
during the last 3 decades of HPLC.
This is also the rationale behind the recent trend in HPLC, the use of sub 2 micron particle columns 
and the development of a specially design of ultra performance HPLC systems to accommodate 
such columns.
w is their respective peak width at 
Rs should be above 1.5 for an accurate 
n essential part of the system suitability measurement 
Rs during the system suitability runs is sometimes called 
Resolution Factor Rs equation is shown in Equation. It includes 
N, the selectivity α and the average of the two peaks' 
Since the plate count increases with the reduction in 
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1.2 ANALYTICAL METHOD DEVELOPMENT7
Method development has following steps: 
Collect information on sample, define separation goals
Need for special HPLC procedure, sample pretreatment, etc.
Choose detector and detector settings
Choose LC method, preliminary run, select best separation conditions
Optimize separation 
conditions
Check for problems, requirement for special procedure
Recover purified material Quantitative calibration Qualitative method
Validate method for release to routine laboratory
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A good method development strategy should require only as many experimental runs as are 
necessary to achieve the desired final result. Finally method development should be as simple as 
possible, and it should allow the use of sophisticated tools such as computer modeling.
The important factors, which are to be taken into account to obtain reliable quantitative analysis, 
are:
1. Careful sampling and sample preparation. 
2. Appropriate choice of the column.
3. Choice of the operating conditions to obtain the adequate resolution of the mixture.
4. Reliable performance of the recording and data handling systems.
5. Suitable integration/peak height measurement technique.
6. The mode of calculation best suited for the purpose
7. Validation of the developed method.
Sample preparation
Samples come in various forms:           
 Solutions ready for injection
 Solutions that require dilution, buffering, addition of an internal standard or other 
volumetric manipulation
 Solids must be dissolved or extracted
 Samples that require pretreatment to remove interferences and/or protect the column or 
equipment from damage.
Most samples for HPLC analysis require weighing and /or volumetric dilution before injection. 
Best results are often obtained when the composition of the sample solvent is close to that of the 
mobile phase since this minimizes baseline upset and other problems. Some samples require a 
partial separation (pretreatment) prior to HPLC, because of need to remove interferences, 
concentrate sample analytes or eliminate “column killers”.
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SELECTING HPLC METHOD AND INITIAL CONDITIONS:
The mode of HPLC can be selected based on the following chart:
                                                                            
                              
                            
                             
             
                                      
In many cases the development of an adequate sample pretreatment can be challenging for 
achieving a good HPLC separation. The samples may be of two types, regular or special. The 
regular samples are typical mixtures of small molecules (<2000Da) that can be separated by normal 
starting conditions.
Reverse
phase
Hydro carbon 
soluble
Adsorption
Organic soluble
Normal phase
Alcohol soluble
Adsorption
MW<2000 Cation
exchange
Electrolyte
Anion exchange
Water soluble
Reverse phase
Sample
Non electrolyte
Normal phase
Organic soluble SFC
MW>2000
SECWater soluble
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GOALS THAT ARE TO BE ACHIEVED IN METHOD DEVELOPMENT
Table No.1: Goals in method development8
Goal Comment
Separation time <5-10 min is desirable for routine procedures.
Quantification
2% for assays; 5% for less-demanding analyses 15% for trace 
analyses.
Pressure
<150 bars is desirable, <200 bars is usually essential (new column 
assumed).
Peak height Narrow peaks are desirable for large signal/noise ratios.
Solvent consumption Minimum mobile-phase use per run is desirable.
OPTIMIZATION OF HPLC METHOD
During the optimization stage, the initial sets of conditions that have evolved from the first stages 
of development are improved or maximized in terms of resolution and peak shape, plate counts, 
asymmetry, capacity factor, elution time, detection limits, limit of quantification and overall ability 
to quantify the specific analyte of interest.
Optimization of a method can follow either of two general approaches:
 Manual
 Computer driven
The manual approach involves varying one experimental variable at a time, while holding all other 
constant and recording changes in response. The variables might include flow rate, mobile or 
stationary phase composition, temperature, detection wavelength and pH.
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This univariate approach to system is slow, time consuming and potentially expensive. However, it 
may provide a much better understanding of the principles and theory involved and of interactions 
of the variables. In the second approach, computer driven automated method development, 
efficiency is optimized while experimental input is minimized. Computer driven automated 
approaches can be applied to many applications. In addition, they are capable of significantly 
reducing the time, energy and cost of all instrumental method development.
The various parameters that include to be optimized during method development are
 Selection of mode of separation.
 Selection of stationary phase.
 Selection of mobile phase.
 Selection of detector.
Selection of Mode of Separation
In reverse phase mode, the mobile phase is comparatively more polar than the stationary phase. For 
the separation of polar or moderately polar compounds, the most preferred mode is reverse phase. 
The nature of the analyte is the primary factor in the selection of the mode of separation. A second 
factor is the nature of the matrix.
A useful and practical measurement of peak shape is peak asymmetry factor and peak tailing factor. 
Peak asymmetry is measured at 10% of full peak height and peak tailing factor at 5%. 
Reproducibility of retention times and capacity factor is important for developing a rugged and 
repeatable method.
Buffers if any and its Strength
Buffer and its strength play an important role in deciding the peak symmetries and separations. 
Some of the most commonly employed buffers are
 Phosphate buffers prepared using salts like KH2PO4, K2HPO4, NaH2PO4, Na2HPO4 etc.
 Phosphoric acid buffers prepared using H3PO4.
 Acetate buffers-Ammonium acetate, Sodium acetate etc.
 Acetic acid buffers prepared using CH3COOH.
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The retention also depends on the molar strengths of the buffer-Molar strength is increasingly 
proportional to retention times. The strength of the buffer can be increased, if necessary to achieve 
the required separations. The solvent strength is a measure of its ability to pull analyte from the 
column. It is generally controlled by the concentration of the solvent with the highest strength.
It is important to maintain the pH of the mobile phase in the range of 2.0 to 8.0 as most columns 
does not withstand to the pH which are outside this range. This is due to the fact that the siloxane 
linkages are cleaved below pH 2.0, while pH values above 8.0, silica may dissolve.
Mobile Phase Composition
Most chromatographic separations can be achieved by choosing the optimum mobile phase 
composition. This is due to the fact that fairly large amount of selectivity can be achieved by 
choosing the qualitative and quantitative composition of aqueous and organic portions.
Most widely used solvents in reverse phase chromatography are Methanol and Acetonitrile. 
Experiments should be conducted with mobile phases having buffers with different pH and 
different organic phases to check for the best separations of analyte peak.
A mobile phase which gives separation of analyte peak and which is rugged for variation of both 
aqueous and organic phase by at least ± 0.2% of the selected mobile phase composition should be 
used.
Selection of Detector
The detector was chosen depending upon some characteristic property of the analyte like UV 
absorbance, florescence, conductance, oxidation, reduction etc. The characteristics that are to be 
fulfilled by a detector to be used in HPLC determination are,
 High sensitivity facilitating trace analysis 
 Negligible baseline noise to facilitate lower detection 
 Large linear dynamic range.
 Low dead volume
 Inexpensive to purchase and operate
Pharmaceutical ingredients do not absorb all UV light equally, so that selection of detection 
wavelength is important. An understanding of the UV light absorptive properties of the organic 
impurities and the active pharmaceutical ingredient is very helpful.
29
For the greatest sensitivity λmax should be used. Ultra violet wavelengths below 200nm should be 
avoided because detector noise increases in this region. Higher wavelengths give greater selectivity.
Performance Calculations
Carrying out system suitability experiment does the performance calculations. System suitability 
experiments can be defined as tests to ensure that the method can generate results of acceptable 
accuracy and precision. 
The requirements for system suitability are usually developed after method development and 
validations have been completed. The criteria selected will be based on the actual performance of 
the method as determined during its validation. For example, if sample retention times form part of 
the system suitability criteria, their variation SD can be determined during validation.
System suitability might then require that retention times fall within a ±3 SD range during routine 
performance of the method.
The USP (2000) defines parameters that can be used to determine system suitability prior to 
analysis. These parameters include plate number (n), tailing factor (T), resolution (RS) and relative 
standard deviation (RSD) of peak height or peak area for respective injections.
The RSD of peak height or area of five injections of a standard solution is normally accepted as one 
of the standard criteria. For assay method of a major component, the RSD should typically be less 
than 1% for these five respective injections.
The plate number and/ or tailing factor are used if the run contains only one peak. For 
chromatographic separations with more than one peak, such as an internal standard assay or an 
impurity method expected to contain many peaks, some measure of separations such as RS is 
recommended. Reproducibility of tR or k value for a specific compound also defines system 
performance.
The column performance can be defined in terms of column plate number. As the plate count is 
more the column is more efficient.
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1.3 ANALYTICAL METHOD VALIDATION9,10
Method validation can be defined as (ICH) “Establishing documented evidence, which provides a 
high degree of assurance that a specific activity will consistently produce a desired result or product 
meeting its predetermined specifications and quality characteristics”.
Method validation is an integral part of the method development; it is the process by which a 
method is tested by the developer or user for reliability, accuracy and preciseness of its intended 
purpose and demonstrating that analytical procedures are suitable for their intended use that they 
support the identity, quality, purity, and potency of the drug substances and drug products.
Data thus generated become part of the methods validation package submitted to Center for Drug 
Evaluation and Research (CDER). Simply, method validation is the process of proving that an 
analytical method is acceptable for its intended purpose.
         All the variables of the method should be considered, including sampling procedure, sample 
preparation, chromatographic separation, and detection and data evaluation. For chromatographic 
methods used in analytical applications there is more consistency in validation practice with key 
analytical parameters includes namely
 System suitability  
 Specificity  
 Accuracy  
 Precision  
 Linearity  
 Limit of Detection  
 Limit of Quantification  
 Ruggedness
 Robustness
SYSTEM SUITABILITY
According to the USP, system suitability tests are an integral part of chromatographic methods. 
These tests are used to verify that the resolution and reproducibility of the system are adequate for 
the analysis to be performed. System suitability tests are based on the concept that the equipment, 
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electronics, analytical operations, and samples constitute an integral system that can be evaluated as 
a whole.  
The purpose of the system suitability test is to ensure that the complete testing system (including 
instrument, reagents, columns, analysts) is suitable for the intended application.
Similar to the analytical method development, the system suitability test Strategy should be revised 
as the analysts develop more experience with the assay. In general, consistency of system 
performance. (E.g.: Replicate injections of the standard) and chromatographic suitability.(Eg: 
Tailing factor, column efficiency and resolution of the critical pair) are the main components of 
system suitability.
During the early stage of the method development process some of the more sophisticated system 
suitability tests may not be practical due to the lack of experience with the method. In this stage, 
usually a more "generic" approach is used. For example, evaluation of the tailing factor to check 
chromatographic suitability, and replicate injections of the system suitability solution to check 
injection precision may be sufficient for an HPLC impurities assay. As the method matures more 
experience is acquired for this method, a more sophisticated system suitability test may be 
necessary.
System suitability is the checking of a system to ensure system performance before or during the 
analysis of unknowns. 
Parameters such as plate count, tailing factors; resolution and reproducibility (%RSD retention time 
and area for six repetitions) are determined and compared against the specifications set for the 
method. These parameters are measured during the analysis of system suitability "sample" that is a 
mixture of main components and expected by-products
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Table No.2:  System suitability parameters and recommendations
Parameter Recommendation
Capacity Factor (k’)
The peak should be well-resolved from other peaks and the void 
volume, generally k’ 1 to 20
Repeatability RSD < 1% for N > 5 is desirable.
Relative retention Not essential as long as the resolution is stated.
Resolution (Rs)
Rs of > 2 between the peak of interest and the closest eluting potential 
interfering (impurity, excipient, degradation product, internal 
standard, etc.
Tailing Factor (T) T of >0.5 and < 2
Theoretical Plates (N) N > 3000
SPECIFICITY/SELECTIVITY
The terms selectivity and specificity are often used interchangeably. According to ICH, the term 
specific generally refers to a method that produces a response for a single analyte only while the 
term selectivity refers to a method that provides responses for a number of chemical entities that 
may or may not be distinguished from each other. If the response is distinguished from all other 
responses, the method is said to be selective. Since there are very few methods that respond to only 
one analyte, the term selectivity is usually more appropriate.  
Specificity is the ability of a method to discriminate between the analyte(s) of interest and other 
components that are present in the sample. Studies are designed to evaluate the degree of 
interference, if any, which can be attributed to other analytes, impurities, degradation products, 
reagent "blanks" and excipients. This provides the analyst with a degree of certainty that the 
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response observed is due to the single analyte of interest. The degree of specificity testing varies 
depending on the method type and the stage of validation. Specificity should be evaluated 
continually through the drug development process. Specificity is sometimes used interchangeably 
with the term "selectivity". The argument over which term is more correct is one of semantics. 
Although there is some dissention, the term "specificity" has been adopted by the regulatory 
guidance documents and should be used to prevent further confusion.
Non-Interference of Placebo
This portion of specificity evaluation applies to the finished drug product only. Excipients present 
in the formulation should be evaluated and must not interfere with the detection of the analyte. 
Individual solutions of each excipient prepared at several times the normal concentration of the 
component in the drug product ensure that any detector response from the excipient will be readily 
visible. Injecting individual solutions of each excipient into the HPLC system in comparison with a 
standard solution of the analyte is one means of performing this experiment. The absence of a peak 
eluting at the retention time of the active ingredient is sufficient to demonstrate specificity for 
excipients. 
Challenge Study
Injecting solutions of known process impurities, degradation products, intermediates, homologues, 
dimers, etc. further challenges the specificity of a method. Identification of these compounds may 
require an extensive search in order to identify all possible species that may be present in the 
sample. For new chemical entities (NCE), this information may not be readily available. Probable 
suspects should be identified by careful review of the synthetic route and manufacturing process to 
identify any likely species that may be present in the sample.
DEGRADATION STUDIES
Degradation studies involve exposing the sample to a variety of stressed conditions to further 
evaluate the specificity of degradation products. In this study, the drug substance, drug product, and 
the combined excipients (or placebos) are each exposed to the stressed conditions. 
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These may include, but are not limited to, heat, light, acidic media, alkaline media, and oxidative 
environments. Other conditions may be used depending on the nature and chemistry of the test 
subject. 
Forced degradation is usually evaluated with not more than 20% degradation of the drug substance, 
although more may be acceptable depending on the particular properties of the drug. A reasonable 
effort should be made to degrade samples in order to identify possible degradation products. If the 
planned experiments do not show any appreciable degradation, the strength and/or exposure time of 
the stress condition may be increased, but degradation is not required for every condition studied. 
There is a point beyond which the stress condition becomes extreme and unrealistic. Sound 
scientific judgment should be used to determine the extent and degree of degradation studies.
ACCURACY
Accuracy is the measure of how close the experimental value is to the true value. Accuracy should 
be established across the specified range of the analytical procedure.
Assay:
Drug Substance
Several methods of determining accuracy are available:
a) Application of an analytical procedure to an analyte of known purity (e.g. reference 
material);
b) Comparison of the results of the proposed analytical procedure with those of a second well-
characterized procedure, the accuracy of which is stated and/or defined.
c) Accuracy may be inferred once precision, linearity and specificity have been established.
Drug Product
Several methods for determining accuracy are available:
a. Application of the analytical procedure to synthetic mixtures of the drug product 
components to which known quantities of the drug substance to be analyzed have been 
added.
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b. In cases where it is impossible to  obtain  samples  of  all  drug  product components, it may 
be acceptable either to add known quantities of the analyte to the drug  product or  to  
compare  the  results  obtained from a second, well  Characterized procedure, the accuracy 
of which is stated and/or defined.
c. Accuracy may be inferred once precision, linearity and specificity have been established.
Impurities (Quantification)
Accuracy should be assessed on samples (drug substance/drug product) spiked with known 
amounts of impurities. In cases where it is impossible to obtain samples of certain impurities and/or 
degradation products, it is considered acceptable to compare results obtained by an independent 
procedure. The response factor of the drug substance can be used. It should be clear how the 
individual or total impurities are to be determined e.g., weight/weight or area percent, in all cases 
with respect to the major analyte.
Recommendations
Accuracy should be assessed using a minimum of 9 determinations over a minimum of 3 
concentration levels covering the specified range (e.g. 3 concentrations / 3 replicates each of the 
total analytical procedure). Accuracy should be reported as percent recovery by the assay of known 
added amount of analyte in the sample or as the difference between the mean and the accepted true 
value together with the confidence intervals.
PRECISION
Precision is the measure of how close the data values are to each other for a number of 
measurements under the same analytical conditions.  ICH has defined precision to contain three 
components: repeatability, intermediate precision and reproducibility. Ruggedness as defined in 
USP XXII <1225>, 1990 incorporates the concepts described under the terms "intermediate 
precision", "reproducibility" and "robustness" of this guide.
Repeatability
(i) Injection Repeatability
Sensitivity is the ability to detect small changes in the concentration of the analyte in the sample. 
Sensitivity can be partially controlled by monitoring the specification 
(system suitability testing).
The sensitivity or precision as measured by multiple injections of a homogeneous sample (prepared 
solution) indicates the performance of the HPLC instrument under the chromatographic conditions 
and day tested. 
The information is provided as part of the validation data and as a system suitability test. The 
specification, as the coefficient of variation in % or relative standard deviation (RSD), set here will 
determine the variation limit of the ana
variation one can expect the results. This assumes that the chromatograph does not malfunction 
after the system suitability testing has been performed. Keep in mind, however, that it does not 
consider variations due to the drug product manufacturing and laboratory sample preparation 
procedures. The set of four duplicate samples were injected sequentially. Variations in peak area 
and drift of retention times are noted. 
Precision refers to the reproducibility of measurement within a set, that is, to the scatter of 
dispersion of a set about its central value. The term ‘set’ is defined as referring to a number (N) of 
independent replicate measurements of some property. One of the most common statist
employed is the standard deviation of a population of observation. Standard deviation is the square 
root of the sum of squares of deviations of individual results for the mean, divided by one less than 
the number of results in the set. The stand
                                    
Standard deviation has the same units as the property being measured.
for injection reproducibility 
lysis. The tighter the value, the more precise or sensitive to 
ard deviation S, is given by
36
ical terms 
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The square of standard deviation is called variance (S2). Relative standard deviation is the standard 
deviation expressed as a fraction of the mean, i.e., S/x. It is sometimes multiplied by 100 and 
expressed as a percent relative standard deviation. It becomes a more reliable expression of 
precision.   
% Relative standard deviation = S x 100 / x
Recommendations
As part of method validation, a minimum of 10 injections with an RSD of 2% is recommended. 
With the methods for release and stability studies, an RSD of 2% for precision of the system 
suitability tests for at least five injections (n=5) for the active drug either in drug substance or drug 
product is desirable. For low-level impurities, higher variations may be acceptable.
(ii) Analysis Repeatability
Determination, expressed as the RSD, consists of multiple measurements of a sample by the same 
analyst under the same analytical conditions. 
For practical purpose, it is often combined with accuracy and carried out as a single study.
(iii) Intermediate Precision
Intermediate precision was previously known as part of ruggedness. The attribute evaluates the 
reliability of the method in a different environment other than that used during development of the 
method. The objective is to ensure that the method will provide the same results when similar 
samples are analyzed once the method development phase is over. Depending on time and 
resources, the method can be tested on multiple days, analysts, instruments, etc.
Intermediate precision in the test method can be partly assured by good system suitability 
specifications. Thus, it is important to set tight, but realistic, system suitability specifications.
LINEARITY
The linearity of a method is its ability to obtain test results that are directly proportional to the 
analyte concentration over a given range. For HPLC methods, the relationship between analyte 
concentration and detector response (peak area or height) is used to make this determination.
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Concentration Ranges
The concentration range used for linearity should be large enough to encompass the desired range 
of the method. A minimum of five concentration ranges should be investigated and a plot of the 
detector response vs. the sample concentration should be generated. It is important that the 
concentration ranges selected for the linearity study are relatively equally spaced throughout the 
range of the method (e.g., 50%, 75%, 100%, 125% and 150%), and not clustered, as this will 
provide a skewed estimation of linearity. 
Acceptance Criteria
Acceptance criteria should be evaluated to ensure that they are meaningful when compared with the 
performance of the method. Table 6 gives a list of suggested acceptance criteria for use in 
evaluating method linearity. The ranges in Table 6 are suggestions only and should be adjusted to 
ensure that all specification limits are within the validated linear range for any given method. Under 
most circumstances, regression coefficient (r) is 0.999. Intercept and slope should be indicated.
Statistical Analysis
Linearity data should be evaluated using appropriate statistical methods. A simple regression line of 
the detector response vs. the analyte concentration is the most common means of evaluation. 
Regulatory agencies require the submission of the correlation coefficient, y-intercept, slope of the 
regression line, and the residual sum of squares for linearity evaluation. 
A graphical representation of the linearity data should also be generated. Additional analysis of the 
deviation of the actual values from the regression line is suggested, especially when the method 
uses a single-point calibration standard. The percent y-intercept is calculated by dividing the y-
intercept by the detector response at the nominal concentration expressed as a percentage. For 
single-point calibration, this value should be less than 1-2% to ensure accurate results.
Table No.3: Statistical analysis
Test Level Range Acceptance criteria
Assay 5 50% to 150% R> 0.999,
Dissolution 5-8 10% to 150% R > 0.99,
Impurity 5 LOQ to 2% R > 0.98
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LIMIT OF DETECTION
These limits are normally applied to related substances in the drug substance or drug product. 
Specifications on these limits are submitted with the regulatory impurities method relating to 
release and stability of both drug substance and drug product.Limit of detection is the lowest 
concentration of analyte in a sample that can be detected, but not necessarily quantified, under the 
stated experimental conditions. With UV detectors, it is difficult to assure the detection precision of 
low-level compounds due to potential gradual loss of sensitivity of detector lamps with age, or 
noise level variation by detector manufacturer. 
At low levels, assurance is needed that the detection and quantification limits are achievable with 
the test method each time. With no reference standard for a given impurity or means to assure 
detectability, extraneous peak(s) could "disappear/appear." A crude method to evaluate the 
feasibility of the extraneous peak detection is to use the percentage claimed for detection limit from 
the area counts of the analyte. Several approaches for determining the detection limit are possible, 
depending on whether the procedure is a non-instrumental or instrumental. 
Based on Visual Evaluation
Visual evaluation may be used for non-instrumental methods but may also be used with 
instrumental methods. The detection limit is determined by the analysis of samples with known 
concentrations of analyte and by establishing the minimum level at which the analyte can be 
reliably detected.
Based on Signal-to-Noise
This approach can only be applied to analytical procedures which exhibit baseline noise. 
Determination of the signal-to-noise ratio is performed by comparing measured signals from 
samples with known low concentrations of analyte with those of blank samples and establishing the 
minimum concentration at which the analyte can be reliably detected. A signal-to-noise ratio 
between 3 or 2:1 is generally considered acceptable for estimating the detection limit.
Based on the Standard Deviation of the Response and the Slope
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The detection limit (DL) may be expressed as:
Where,      σ = the standard deviation of the response
               S = the slope of the calibration curve
The slope S may be estimated from the calibration curve of the analyte. The estimate of s may be 
carried out in a variety of ways, for example
Based on the Standard Deviation of the Blank
Analyzing an appropriate number of blank samples and calculating the standard deviation of these 
responses perform measurement of the magnitude of analytical background response.
Based on the Calibration Curve
A specific calibration curve should be studied using samples containing an analyte in the range of 
DL. The residual standard deviation of a regression line or the standard deviation of y-intercepts of 
regression lines may be used as the standard deviation.
Recommendations
The detection limit and the method used for determining the detection limit should be presented. If 
DL is determined based on visual evaluation or based on signal to noise ratio, the presentation of 
the relevant chromatograms is considered acceptable for justification.
In cases where an estimated value for the detection limit is obtained by calculation or extrapolation, 
this estimate may subsequently be validated by the independent analysis of a suitable number of 
samples known to be near or prepared at the detection limit.
LIMIT OF QUANTIFICATION
Limit of quantification is the lowest concentration of analyte in a sample that can be determined 
with acceptable precision and accuracy under the stated experimental conditions. Several 
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approaches for determining the quantification limit are possible, depending on whether the 
procedure is a non-instrumental or instrumental. 
Based on Visual Evaluation
Visual evaluation may be used for non-instrumental methods but may also be used with 
instrumental methods. The quantification limit is generally determined by the analysis of samples 
with known concentrations of analyte and by establishing the minimum level at which the analyte 
can be quantified with acceptable accuracy and precision.
Based on Signal-to-Noise Approach
This approach can only be applied to analytical procedures that exhibit baseline noise. 
Determination of the signal-to-noise ratio is performed by comparing measured signals from 
samples with known low concentrations of analyte with those of blank samples and by establishing 
the minimum concentration at which the analyte can be reliably quantified. A typical signal-to-
noise ratio is 10:1.
Based on the Standard Deviation of the Response and the Slope
The quantification limit (QL) may be expressed as:
                                  
Where,
             σ = the standard deviation of the response
              S = the slope of the calibration curve
The slope S may be estimated from the calibration curve of the analyte. The estimate of s may be 
carried out in a variety of ways.
Based on Standard Deviation of the Blank
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Measurement of the magnitude of analytical background response is performed by analyzing an 
appropriate number of blank samples and calculating the standard deviation of these responses.
Based on the Calibration Curve
A specific calibration curve should be studied using samples, containing an analyte in the range of 
QL. The residual standard deviation of a regression line or the standard deviation of y-intercepts of 
regression lines may be used as the standard deviation. 
Recommendations
The quantification limit and the method used for determining the quantification limit should be 
presented. The limit should be subsequently validated by the analysis of a suitable number of 
samples known to be near or prepared at the quantification limit. Otherwise the information that is 
expressed as % area or height of the drug substance peak from the same HPLC chromatogram will 
be biased. It should also be noted that the extraneous peak using area count does not consider the 
detection response that depends on the UV extinction coefficient or absorptivity of the compound.
RUGGEDNESS
The ruggedness of an analytical method is the degree of reproducibility of test results obtained by 
the analysis of the same samples under a variety of conditions, such as different laboratories, 
analysts, instruments, reagents, elapsed assay times, assay temperatures, or days. It is normally 
expressed as the lack of influence on test results of operational and environmental variables of the 
analytical method. 
Method Ruggedness is defined as the reproducibility of results when the method is performed under 
actual use conditions. Method ruggedness may not be known when a method is first developed, but 
insight is obtained during subsequent use of that method. 
Recommendations
The ruggedness of an analytical method is determined by analysis of aliquots from homogeneous 
lots in different laboratories, by different analysts, using operational and environmental conditions 
that may differ but are still within the specified parameters of the assay. 
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The degree of reproducibility of test results is then determined as a function of the assay variables. 
This reproducibility may be compared to the precision of the assay under normal conditions to 
obtain a measure of the ruggedness of the method.
ROBUSTNESS
ICH defines robustness as a measure of the method's capability to remain unaffected by small, but 
deliberate variations in method parameters. Robustness can be partly assured by good system 
suitability specifications. The evaluation of robustness should be considered during the 
development phase and depends on the type of procedure under study. It should show the reliability 
of an analysis with respect to deliberate variations in method parameters. 
If measurements are susceptible to variations in analytical conditions, the analytical conditions 
should be suitably controlled or a precautionary statement should be included in the procedure. One 
consequence of the evaluation of robustness should be that a series of system suitability parameters 
(e.g., resolution test) is established to ensure that the validity of the analytical procedure is 
maintained whenever used.
Examples of typical variations are:
 Stability of analytical solutions
 Extraction time
In the case of liquid chromatography, examples of typical variations are
 Influence of variations of pH in a mobile phase
 Influence of variations in mobile phase composition
 Different columns (different lots and/or suppliers)
 Temperature
 Flow rate.
In the case of gas chromatography, examples of typical variations are
 Different columns (different lots and/or suppliers)
 Temperature.
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2. DRUG PROFILE
OLMESARTAN MEDOXIMIL13:-
Chemical structure            :                                                                                   
IUPAC name                     :       5-Methyl-2-oxo-1,3-dioxol-4-ylmethyl-4-(1-hydroxy-                    
1-methylethyl)-2-propyl-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]imidazol-5-carboxylate.
Molecular Formula        :       C29-H30-N6-O6.
Molecular Weight          :        558.59
CAS number                 :         0144689-63-4
General properties:-
Colour                           :          White to off-white powder
State                              :         Crystalline powder
Solubility                      :          Insoluble in water, slightly soluble in ethanol, methanol.
Melting point              :           175-1800C
Dosage form              :            Tablets
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Category                     :           Anti hypertensive agent
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CILNIDIPINE14
Chemical structure            :    
                                                                              
IUPAC name                     :       o3-(2-methoxyethyl) O5-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-
4-(3-nitrophenyl)-1,4-dihydropyridine- 3,5-dicarboxylate
Molecular Formula        :       C27-H28-N2-O7
Molecular Weight          :        492.52
CAS number                 :         132203-70-4
General properties:-
Colour                           :         light yellowish 
State                              :         Crystalline powder
Solubility                      :          Insoluble in water, slightly soluble in ethanol, methanol.
Melting point              :           107-1120C
Dosage form              :            Tablets
Category                     :           calcium channel blocker
Dosage form : Tablets
Marketed formulations: Nexovas-O
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3. REVIEW OF LITERATURE
 V GANDHI , et al., (2013)22 developed a simple, accurate reverse phase liquid 
chromatographic method for estimation of simultaneous quantification of Telmisartan and 
Cilnidipine as the bulk drug and in tablet dosage forms. Separation was carried out on Jasco 
HPLC system equipped with HiQ sil C18 HS column (250 x 4.6mm i.d) and PDA detector 
using Methanol: 40mM Potassium dihydrogen ortho phosphate buffer (pH3) (90:10, v/v)as the 
mobile phase and detection was carried out at 245nm .Results were linear in the range of 1-
10µg/ml for Cilnidipine and 5-30µg/ml for Telmisartan. The method was successfully applied 
for the analysis of drug in pharmaceutical formulation. Results of the analysis were validated 
statistically and by the recovery studies.
 Manohara yagina  et al., (2013)`19        A rapid simple and specific reversed phase HPLC 
method has been developed for estimation of Cilnidipine in Pharmaceutical formulation. 
HPLC analysis was performed on a C18 column using a 80:20 (v/v) mixture of Methanol and 
0.05M Phosphate buffer at pH 3.0 as isocratic mobile phase at a flow rate of 1ml/min UV 
detection was carried out at 254 nm. The method was validated for accuracy, Precision, 
linearity, specificity. Validation revealed that the method is specific accurate precise relative 
and reproductive. Good linear correlation coefficient were obtained for calibration plots in the
ranges tested. Limit od detection was 0.179µg/ml and limit if quantification was 0.544µg/ml. 
Intraday and interday RSD of retention time and peak areas are less than 1.729%. and recovey 
was obtained between 99.95% and 101.09%. The estimated HPLC method is appropriate 
enabling efficient quantitative analysis of Cilnidipine in pharmaceutical formulations.
 Hamrapukar et al., (2013)16 stability testing of an active substance or finished product 
provide evidence as to that quality it remains acceptable upto the stated period under storage 
condition as on label . With this objective a stability indicating HPLC has been established for 
the analysis of Olmesartan Medoximil in the presence of degradation products . The drug was 
subjected to sterss conditions of hydrolysis, photolysis , oxidation, thermal degradation. 
Extensive degradation was found in acid medium and alkaline medium. Minimum degradation 
in thermal degradation. While no degradation in photolytic condition .successful separation of 
drug from degradation product formed under stress condition was achieved on C18 column 
using Methanol and water (60:40% v/v) pH 3.75 was adjusted with 10mM ortho phosphoric 
acid mobile phase. Flow rate was 1ml/min and detector was set to at 270nm. The method was 
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validated for linearity , range , precision, and accuracy, limit of detection and limit of 
quantification .
 Reema H, et al., (2013)21A simple, precise, and accurate RP-HPLC method has been developed 
and validated for the simultaneous assay of Telmisartan and Cilnidipine in tablets. Isocratic RP-
HPLC method was developed on Waters C18 mm, 5μm column using mobile phase as 
acetonitrile (ACN): buffer pH 3.0 with orthophosphoric acid (68:32) at a flow rate of 
1.0mL/min and the detection was carried out at 245nm using photodiode array detector. 
Forced degradation study was carried out by oxidation, hydrolysis, photolysis, and heating the 
drug. The method was validated for specificity, linearity, precision, accuracy, robustness, and 
solution stability. The method was found to be linear in the concentration range of 40–
160μg/mL with correlation coefficient of 0.9990 for Telmisartan and 10–40μg/mL with 
correlation coefficient of 0.9989 for Cilnidipine. Degradation products produced as a result of 
stress studies did not interfere with the detection of agomelatine; therefore, the assay can be 
considered to be stability indicating.
 Padmanabh B et al., (2012) 20 A simple HPTLC method for the determination of Cilnidipine 
and Telmisartan in combined dosage form has been developed and validated. The separation 
was carried out on Merck aluminium plates precoated with silica gel 60 F254 using Toulene : 
Methanol : Ethyl acetate (8:2:1 v/v/v) as the mobile phase and detection was carried out in 
260nm. Results were in the linear range of 200-1200 ng/gm for Cilnidipine and 400-
4800ng/gm for Telmisartan. The method was successfully applied for the analysis of drugs in 
pharmaceutical formulation.The results of analysis were statistically and by recovery studies..
Present method can be applied for the determination of  Olmesartan medoxomil in quality 
control of formulation without interference of the excipients
 Kameswrao , et al., (2012)17 The present method provides the detailed description of 
development and validation of a simple stability indicating re- verse phase column liquid 
chromatographic method for Olmesartan in the presence of its impurities namely Imp-A, 
Imp-B, Imp-C, Imp-D, Imp-E, Imp-F and Imp-G and degradation products generated from 
forced degradation studies. The drug substance was subjected to stress conditions of 
aqueous hydrolysis, Oxidative, photolytic and thermal stress degradation. The degradation 
of Olmesartan was observed under acid hydrolysis, base hydrolysis and peroxide. The drug 
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was found to be stable to other stress conditions attempted. Successful separation of the 
drug from synthetic impu- rities and degradation products formed under stress conditions 
was achieved on symmetry C18, 150 mm × 4.6 mm, 5 μ column using a phosphate buffer, 
Acetonitrile and Milli Q water. The developed LC method was validated with respect to 
specificity, linearity, accuracy, precision, raggedness and robustness. The assay method was 
found to be linear in the range of 250 μg·mL–1 to with 1000 μg·mL–1 correlation 
coefficient of 0.9999 and the linearity of the impurities was es- tablished from LOQ to 
0.4%. Recoveries of assay and impurities were found between 98.5% and 101.2%. The 
devel- oped LC method to determine the related substances and assay determinations of 
Olmesartan can be used to evaluate the quality of regular production samples and stability 
samples. 
 Kumanan, et al., (2011)18 stability testing of an active substance or finished product provide 
evidence as to that quality it remains acceptable upto the stated period under storage condition 
as on label . With this objective a stability indicating HPLC has been established for the
analysis of Olmesartan Medoximil in the presence of degradation products . The drug was 
subjected to stress conditions of hydrolysis, photolysis , oxidation, thermal 
degradation.successful separation of drug from degradation product formed under stress 
condition was achieved on Luna C18 column using Acetonitrile and water (50:50% v/v) pH 
4.5 was adjusted with 10mM Potassium hydrogen phosphate mobile phase. Flow rate was 
1ml/min and detector was set to at 258nm. The method was validated for linearity , range , 
precision, and accuracy, limit of detection and limit of quantification .
 Chaitanya Prasad, et al., (2011)15 Reversed phase high  performance liquid  Chromatographic 
method was developed and validated for the  estimation of  Olmesartan medoxomil in bulk and 
formulation. Selected mobile phase was a  combination of phosphate buffer with pH adjusted at 
2.8 and acetonitrile (35:65%  v/v) and wavelength selected was 250 nm. Retention time of  
Olmesartan medoxomil  was 2.591 min. Linearity of the method was found to be  50-150 μg/ml, 
with the  regression coefficient of 0.9993. Quantification was done  by calculating area of the  
peak and the detection limit and quantification limit  was 0.02μg/ml and 0.09μg/ml,  
respectively. There was no significant  difference in the intraday and inter day analysis  of 
Olmesartan medoxomil determined for  three different concentrations using this method.
 Chaitanya Prasad, et al., (2011)15 Reversed phase high performance liquid  Chromatographic 
method was developed and validated for the estimation of  Olmesartan medoxomil in bulk and 
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formulation. Selected mobile phase was a  combination of phosphate buffer with pH adjusted at 
2.8 and acetonitrile (35:65%  v/v) and wavelength selected was 250 nm. Retention time of  
Olmesartan medoxomil  was 2.591 min. Linearity of the method was found to be 50-150 μg/ml, 
with the  regression coefficient of 0.9993. Quantification was done by calculating area of the  
peak and the detection limit and quantification limit was 0.02μg/ml and 0.09μg/ml,  
respectively. There was no significant  difference in the intraday and inter day analysis  of 
Olmesartan medoxomil determined for three different concentrations using this method.
4. AIM AND OBJECTIVE 
   On the literature survey most of literatures related to HPTLC and HPLC methods have been 
reported determination of Cilnidipine and Olmesartan Medoximil separately . Few methods 
reported related to HPLC in tablet dosage form . Hence an attempt has made to develop a HPLC 
method for the determination of Cilnidipine and Olmesartan Medoximil in API and pharmaceutical 
dosage forms.
   Present work is aimed at to develop a new, simple, fast, rapid, accurate, efficient and reproducible
RP-HPLC method for the analysis of Olmesaratn medoximil and Cilnidipine in tablet dosage form 
and developed method will be validated according to ICH (Q2b) 14 guidelines.  
OBJECTIVE
o To develop rapid, accurate, method with good reproducibility.
o To develop economic assay methods.
o To develop sensitive methods for analysis.
o To develop a precise method of analysis.
o To develop a selective method of estimation.
5. PLAN OF WORK
The experimental work has been planned as follows
STEP 1-
 Study of physico-chemical properties of drugs (pH, pka, solubility, and molecular weight)
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 Preparation of drug standard and sample
 Develop simple, rapid and specific HPLC method for the quantitative simultaneous 
estimation of Olmesartan medoximil and Cilnidipine  in tablet dosage form.
 Selection of stationary phase
• Selection of mobile phase
• Preparation of solutions
• Optimizing the chromatographic conditions
STEP 2-
• To validate the newly developed methods in accordance with the analytical validation 
parameters mentioned as ICH guidelines(Q2B)
6. MATERIALS AND METHODS
MATERIALS
Drug sample:
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Olmesartan Medoximil and Cilnidipine reference standards are provided from Dr.reddys 
Hyderabad, India 
REAGENTS AND CHEMICALS:
 Ammonium acetate
 Formic acid (0.1%)
 Methanol
 Olmesartan Medoximil (API)
 Cilnidipine (API)
 HPLC water (AR grade)
INSTRUMENTS USED:
Table No.4: Instruments used
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INSTRUMENT MAKE
HPLC System Dionex
UV-Spectrometer Perkin elmer
Analytical Balance Shimadzu
Sonicator Bandelin sonorex
METHOD DEVELOPMENT AND OPTIMISATION
Table No.5: Chromatographic conditions
Instrument DIONEX
Column SYNERGIFUSION RP,150×4.6mm,5µ
Detector PDA
Flow rate 1ml /min
Wavelength 254nm
Injection volume 5µl
Column temperature 370C
Mobile phase 0.1% FA +Ammonium acetate : 
Methanol(20:80)
Elution technique Isocratic
METHOD DEVELOPMENT AND OPTIMISATION
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The objective of this experiment was to optimize the assay method for the estimation of 
Olmesartan Medoximil and Cilnidipine based on the literature survey. So here the trials mentioned 
describes how the optimization was done.
TRIAL-1
Preparation of mobile phase:
The mobile phase was prepared by mixing   ammonium bicarbonate and methanol in the ratio of 
50:50. The mobile phase is then sonicated using ultra sonicator for removing impurities and 
dissolved gases.
CHROMATOGRAPHIC CONDITIONS 
 Technique: HPLC
 Column: SYNERGI RP FUSION,150×4.6mm,5µ
 Mobile phase:- ammonium bicarbonate:methanol 50:50
 Column temperature: 400C
 Wavelength: 254nm
 Flow rate: 1ml/min
 Run time: 8min
 Detector: PDA
 pressure: 1200-1300 psi
 NOTE: Merging problems faced
TRIAL-2
Preparation of mobile phase:The mobile phase was prepared by mixing ammonium bicarbonate  
and methanol in the ratio of 40:60. The mobile phase is then sonicated using ultra sonicator for 
removing impurities and dissolved gases.
CHROMATOGRAPHIC CONDITIONS 
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 Technique: HPLC
 Column: SYNERGI FUSION RP COLUMN  ,150×4.6mm,5µ
 Mobile phase:- ammonium bicarbonate:acetonitrile 40:60
 Column temperature: 400C
 Wavelength: 254nm
 Flow rate: 1ml/min
 Run time: 8min
 Detector: PDA
 pressure: 1200-1400 psi
NOTE: got an uncleared Rt’s
OPTIMIZEDMETHOD
PREPARATION OF MOBILE PHASE:
The mobile phase was prepared by mixing ammonium acetate and methanol in the ratio of 20:80. 
The mobile phase is then sonicated using ultra sonicator to removing impurities and dissolved 
gases.
CHROMATOGRAPHIC CONDITIONS 
 Technique: HPLC
 Column: SYNERGI FUSION RP 150×4.6mm,5µ
 Mobile phase:- ammonium acetate:methanol:20:80
 Column temperature: 370C
 Wavelength: 254nm
 Flow rate: 1ml/min
 Run time: 8min
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 Detector: PDA
 Pressure: 1200-1400 psi
METHODOLOGY
3.2.1Assay method development:
3.3 METHOD DEVELOPMENT OF LMESARTAN MEDOXIMIL AND CILNIDIPINE 
BYRP-HPLC
The method should be developed mainly based on pka concept of drug and also different mobile 
phase composition, flow rate, λmax, different columns and column temperature. Olmesartan 
medoximil  has two pka values that are 4.3, and 13 and Cilnidipine has pka of 2.3 .Generally pH of 
buffer solution should be select ± 1 of pka value of drug. In this method pKa value of 4.3 for 
olmesartan was selected because in HPLC, column may damage solutions with pH more than 10. 
So pka 13 of Olmesartan Medoximil was eliminated. Finally good peak was obtained at pH 3.5 of 
buffer and retention time also less than compared to other trials. So the method was optimized at 
these conditions.
Further validation study should be performed as per ICH guidelines.
Preparation of solutions:
Buffer Preparation: 
Add 0.768gms of ammonium acetate in 1000ml of Millipore water and sonicate it in sonicator for 
30mins and adjust the pH to 3.5 ± 0.05 with formic acid..
Mobile phase
Prepare a filtered (0.45µ) and degassed mixture of buffer preparation and methanol in ratio of 20: 
80 v/v respectively.
Preparative Steps for Assay method development:
Standard Preparation:
Weigh and transfer accurately 200 and 100  mg of Olmesartan Medoximil and Cilnidipine 
repectively working Standard into a 100 ml clean dry volumetric flask, sonicate to dissolve. 
Cool the solution to room temperature 
volumetric flask and dilute with mobile phase.
Sample preparation:  
Weigh and finely powder 20 tablets and Transf
10ml of clean, dry, volumetric flask. Add about 10ml of mobile phase
15 min and sonicated for 30 min with occasionally 
and dilute volume with solvent mixture. Centrifuge the solution at 3000
transfer 1.0 ml above solution
Standard chromatogram-1
Sample chromatogram-2
METHOD VALIDATION
The validation protocol is applicable to quantitative analytical method
estimation of active content in support of regulatory requirements. This procedure covers the 
following parameters.
1) System Suitability
. Then transfer 5.0 ml above solution into 50 ml 
er the powder equivalent to 30mg of Nexovas
, shake on orbital shaker for 
shaking. Cool the solution to room temperature 
RPM for 15 min. Then 
into 10 ml volumetric flask and dilute with mobile phase
- Assay, which is used for the 
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2) Specificity
         3) Method precision
4) Accuracy
5) Linearity
          6) Robustness
SYSTEM SUITABILITY
System suitability is defined by ICH as "the checking of a system performance, before or during 
analysis of unknowns, to ensure system performance."
System suitability criteria may include such factors as plate count, tailing, retention, and/or 
resolution, tailing factor. System suitability criteria should also include a determination of 
reproducibility (%RSD).
RETENTION TIME: 
Retention time the difference in time between the point of injection and appearance of peak 
maximum.
RESOLUTION:
Resolution is the measure of the extent of separation of two components and the base line 
separation achieved. It can determine by following formula
Rs = 2(Rt2-Rt1)/W1+W2
Where n= no of theoretical plates 
Rt = Retention time
W= peak width at base 
NO OF THEORETICAL PLATES: 
n= 16* Rt2/ W2
Where n= no of theoretical plates  
Rt = Retention time
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W= peak width at a base 
THEORETICAL PLATE (PLATE THEORY):
A theoretical plate is an imaginary or hypothetical unit of a column where distribution of solute 
between stationary phase and mobile phase has attained equilibrium.
HETP (HEIGHT EQUIVALENT TO A THEORETICAL PLATE)  
A theoretical plate count decides the efficiency of separation. And if HETP is less, The column is 
more efficient and vice versa.
HETP= length of the column /No of theoretical plates.
VANDEEMETER PRINCIPLE:
HETP is given by the VANDEEMETER Equation 
HETP = A+B/u+Cu
Where A= Eddy's Diffusion term 
B= Longitudinal Diffusion Term
C= Effect of Mass Transfer which depends on flow rate 
u=flow rate
Preparation of standard stock solution:
Weigh accurately 20mg of Olmesartan medoximil and 10mg of Cilnidipine iin a 10 ml 
standard flask add diluent and   sonicate for half an hour. Now make up to the mark by adding 
mobile phase. Then transfer the 0.1ml of above solution into 10ml volumetric flask and dilute with 
mobile phase
Procedure: Injected 5μl of standard stock solution in replicate (5 times) and recorded the peak area 
response of Olmesartan Medoximil and cilnidipine. Calculate the % RSD for the response of the 
standard Solution (for 5 replicates).
Acceptance criteria: The % RSD should not be more than 2.0%, USP tailing should not be more 
than 2.5, and Theoretical plates should not be less than 1500
SYSTEM SUITABILITY (chromotogram-3)
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Table No.6: System suitability parameters for Olmesartan Medoximil
Table No.7: System suitability parameters for Cilnidipine
Injection no Drug Area(mAU*) %Area
Retention 
time
Theoretical 
plate
Tailing 
factor
1
Olmesartan 
medoximil
40.78 53.71 2.44 2633 1.1
2
Olmesartan 
medoximil
40.79 53.70 2.47 2641 1.3
3
Olmesartan 
medoximil
40.76 53.22 2.49 2621 1.4
4
Olmesartan 
medoximil
40.80 53.45 2.46 2606 1.3
5
Olmesartan 
medoximil
40.78 53.47 2.51 2656 1.1
Mean 40.782
0.014832
0.03
STD.DEV
%RSD
Injection no Drug Area(mAU*) %Area
Retention 
time
Theoretical 
plate
Tailing 
factor
1 Cilnidipine 31.613 47.63 4.75 3539 1.1
2 Cilnidipine 31.655 47.67 4.76 3553 1.3
3 Cilnidipine 31.689 47.68 4.78 3509 1.4
4 Cilnidipine 31.699 47.69 4.72 3452 1.3
5 Cilnidipine 31.683 47.61 4.76 3469 1.1
Mean 31.6678
0.034716 
0.107
STD.DEV
%RSD
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SPECIFICITY
Ability of an analytical method to measure the analyte free from interference due to other 
components.
PROCEDURE
To demonstrate the specificity blank, standard Olmesartan medoximil in the concentration of 
100mcg/ml, Cilnidipine 100mcg/ml and blend solution 100mcg/ml  were prepared and 
chromatogram was recorded
Preparation of standard solution:
Weigh accurately 20mg of Olmesartan medoximil and 10mg of Cilnidipine iin a 10 ml 
standard flask add diluent and  sonicate for half an hour. Now make up to the mark by adding  
mobile phase.Then transfer the 0.1ml of above solution into 10ml volumetric flask and dilute with 
mobile phase
Preparation of sample solution:
Weigh and finely powder 20 tablets and Transfer the powder equivalent to 30mg of Nexovas-o into 
10ml of clean, dry, volumetric flask. Add about 10ml of mobile phase, shake on orbital shaker for 
15 min and sonicated for 30 min with occasionally shaking. Cool the solution to room temperature 
and dilute volume with solvent mixture. Centrifuge the solution at 3000 RPM for 15 min. Then 
transfer 0.1 ml above solution into 10 ml volumetric flask and dilute with mobile phase
Acceptance criteria: There should be no interference peak due to other components
SPECIFICITY(chromotogram-4)
Table No.8: Specificity
                                                
Report: From the results method was said t
LINEARITY
The linearity of an analytical procedure is its ability (within given range) to obtain test results 
which are directly proportional to the concentration (amount) of Analyte in the sample
PREPARATION OF STANDARD STOCK SOLUTION: 
Accurately weighed 20mg of Olmesartan Medoximil and 10mg of CIlnidipine  in a 10 ml standard 
flask respectively and dilute with diluent , sonicate 30 minutes . Finally make upto the volume by 
using mobile phase. From above solution the following dilutions are made.
Preparation of 10% standard solution:
From the above solutions take take 0.02ml of Olmesar
standard flask and further dilute upto the mark with mobile phase in order to get the concentration 
20mcg/ml.  
Preparation of 25% standard solution:
Injection
1
1 Olmesartan Medoximil
1
Blend soln Olmesartan Medoximil
Cilnidipine
o be specific for test results
(for Olmesartan Mediximil)
tan Medoximil and Cilnidipine in a 10 ml 
Drug Area % Area RT
Blank Nil Nil Nil
39.428 100.00 2.46
Cilnidipine 32.897 100.00 4.73
41.865 52.867 2.44
31.986 47.592 4.74
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From the above solutions take 0.05ml of Olmesartan Medoximil and Cilnidipine in a 10 ml 
standard flask and further dilute up to the mark with mobile phase in order to get the concentration 
50mcg/ml.  
Preparation of 50% standard solution:
From the above solutions take 0.1ml of Olmesartan Medoximil and Cilnidipine in a 10 ml standard 
flask and further dilute up to the mark with mobile phase in order to get the concentration 
100mcg/ml.  
Preparation of 75% standard solution:
From the above solutions take 0.15ml of Olmesartan Medoximil and Cilnidipine in a 10 ml 
standard flask and further dilute up to the mark with mobile phase in order to get the concentration 
150mcg/ml.  
Preparation of 100% standard solution:
From the above solutions take 0.2ml of Olmesartan Medoximil and Cilnidipine in a 10 ml standard 
flask and further dilute upto the mark with mobile phase in order to get the concentration 
200mcg/ml.  
PROCEDURE
Different standard concentrations of 20, 50, 100, 150, 200mcg/ml were prepared and one injection 
from each concentration was used to get chromatogram.
Acceptance criteria
The linearity regression should not be less than 0.995.
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Linearity for Olmesartan Medoximil
Table No.9: 
y = 0.381x + 1.381
R² = 0.999
0
10
20
30
40
50
60
70
80
90
0 50 100 150 200 250
Ar
ea
Concentration  
Olmesartan medoximil
area(mAU*)
Serial no Concentration(mcg/ml) Area (mAU*)
1 20 8.216
2 50 21.389
3 100 39.430
4 150 58.956
5 200 77.371
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Linearity for Cilnidipine
Table No.10: 
LINEARITY (chromotogram-5)
y = 0.290x + 0.593
R² = 0.995
0
10
20
30
40
50
60
70
0 50 100 150 200 250
Ar
ea
Concentration
Cilnidipine
area(mAU*)
Serial no Concentration(mcg/ml) Area (mAU*)
1 20 5.552
2 50 14.502
3 100 31.541
4 150 45.443
5 200 57.072
ACCURACY:
The accuracy of an analytical procedure is the closeness of test results obtained by that procedure to 
the true value. The accuracy of analytical should be established across its range.
Determination: Accuracy is determined by three ways:
i) Comparison to a reference standard
ii) Recovery of the analyte spiked into blank matrix
iii) Standard addition of the analyte
Procedure:The accuracy of the method was determined by an
solutions approximately 80%, 100%, and 16
in the following table.
Preparation of standard stock solution:
Weigh accurately 20mg of Olmesartan medoximil and 10mg of Cilnidipine iin a 10
standard flask add diluent and  sonicate for half an hour. Now make up to the mark by adding  
mobile phase.Then transfer the 0.1ml of above solution into 10ml volumetric flask and dilute with 
mobile phase
Preparation of sample solution:
Weigh and finely powder 20 tablets and Transf
10ml of clean, dry, volumetric flask. Add about 10ml of mobile phase
15 min and sonicated for 30 min with occasionally 
and dilute volume with solvent mixture. Centrifuge the solution at 3000
transfer 0.1 ml above solution into 10
Acceptance criteria:
alyzing Atorvastatin and amlodipine 
0% of standard level and the results were su
er the powder equivalent to 30mg of Nexovas
, shake on orbital shaker for 
shaking. Cool the solution to room temperature 
RPM for 15 min. Then 
ml volumetric flask and dilute with mobile phase
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% recovery should be in the limits of 98% to 102%
Table No: 11 Accuracy
Olme Level Area(%mAU*) %recovery Cil Level Area 
(mAU*)
% 
recovery
80% A 31.345 98.75% 80% A 23.889 100.425
B 31.623 B 23.787
C 31.473 C 24.008
100% A 39.910 101.7% 100% A 29.321 100.05
B 41.120 B 30.081
C 39.421 C 29.456
160 A 63.125 101.65% 160% A 47.413 101.39%
B 63.797 B 47.615
C 63.129 C 47.893
Average 100.7% Average 100.62
Accuracy 80( Chromatogram 6
Accuracy 100(chromatogram-7
Accuracy 160(chromatogram-8
)
)
)
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Report:The method was found to be accurate as the % recove
Medoximil 98.75% - 101.65%, 
acceptance range of 98-102
METHOD PRECISION OR REPEATABI
Preparation of sample stock solution:
Weigh and finely powder 20 tablets and Transf
10ml of clean, dry, volumetric flask. Add about 10ml of mobile phase
15 min and sonicated for 30 min with occasionally 
and dilute volume with solvent mixture. Centrifuge the solution at 3000
transfer 0.1 ml above solution
Procedure: Injected 5μl of standard stock solution in replicate (5
response of Olmesartan Medoximil and cilnidipine
standard Solution (for 5 replicates).
Acceptance criteria: The result obtained from the sample preparation shall be calculated and it 
should be within the limit of 98% to 102% from the assay value and RSD should not more than 
2.0%
ry ranged from Olmesartan 
Cilnidipine 100.425% - 101.39%, which is well within 
LITY:
er the powder equivalent to 30mg of Nexovas
, shake on orbital shaker for 
shaking. Cool the solution to room temperature 
RPM for 15 min. Then 
into 10 ml volumetric flask and dilute with mobile ph
times) and recorded the pea
. Calculate the % RSD for the response
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k area 
of the 
Table No.12: method precision
Injection Olmesartan Medoximil
Area(mAU*)
1 39.910
2 41.120
3 39.421
4 40.807
5 40.785
Avg
Std dev
%RSD
Report: As the results were within the acceptable limits
IMMEDIATE PRECISION (chromotogram
Intermediate Precision/Ruggedness 
To evaluate the intermediate precision (also known as Ruggedness) of the method,   
Precision was performed on different day by using different make column of same dimensions.  
Preparation of stock solution
Weigh and finely powder 20 tablets and Transf
10ml of clean, dry, volumetric flask. Add about 10ml of mobile phase
15 min and sonicated for 30 min with occasionally 
Cilnidipine
%Area Assay Area(mAU*) %Area
53.17 99.36 29.321 48.89
52.98 99.00 30.081 48.98
53.22 99.45 29.456 48.95
52.99 99.02 31.700 48.11
52.82 98.71 31.689 48.15
99.108
0.299
0.30
, all the methods provide good precision
-9)
er the powder equivalent to 30mg of Nexovas
, shake on orbital shaker for 
shaking. Cool the solution to room temperature 
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Assay
102.79
102.98
102.92
101.14
101.24
102.214
0.937
0.917
-o into 
and dilute volume with solvent mixture. Centrifuge the solution at 3000
transfer 0.1 ml above solution
Procedure
The standard solution was injected for three 
HPLC. The %RSD for the area of three 
        Acceptance Criteria
 The % RSD for the area of three 
Intermediate precision  (chromotogram
RPM for 15 min. Then 
into 10 ml volumetric flask and dilute with mobile phase
times and measured the area for all three 
replicate injections was found to be within the specified limits.
sample injections results should not be more 
-10,11)
72
injections in 
than 2%
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Table No.13: Immediate  precision
Injection Olmesartan Medoximil Cilnidipine
Area (mAU*) %Area Assay Area (mAU*) %Area Assay
1 39.910 53.17 99.36 29.321 48.89 102.64
2 41.120 52.98 99.00 30.081 48.98 102.84
3 39.421 53.22 99.45 29.456 48.95 102.77
Avg
Std dev
%RSD
99.27 102.75
0.238 0.1014
0.2 0.098
Table No.14: intermediate precision
Injection Olmesartan Medoximil Cilnidipine
Area (mAU*) %Area Assay Area (mAU*) %Area Assay
1 41.832 52.80 98.67 31.889 48.29 101.53
2 40.889 52.71 98.5 31.203 48.36 101.68
3 40.145 52.81 98.69 30.749 48.21 101.36
Avg
Std dev
%RSD
98.62 101.52
0.1044 0.160
0.10 0.15
ROBUSTNESS
 ICH defines the robustness of an analytical procedure as a measure of its capacity to remain 
unaffected by small, but deliberate variations in method parameters. It provides an 
indication of the procedure’s reliability during normal usage.
 Robustness tests examine the effect that operational parameters have on the analysis results. 
 For the determination of a method’s robustness, a number of method parameters, such 
pH, flow rate, column temperature, injection volume, detection wavelength or mobile phase 
composition, are varied within a realistic range, and the quantitative influence of the 
variables is determined. If the influence of the parameter is within a previouslyspecified 
tolerance, the parameter is said to be with
PROCEDURE:
To demonstrate the robustness of the method standard solution concentration
prepared, from this solution three
Mobile phase composition:
Actual mobile phase composition 20:80(wa
mobile phase composition 27:.73
ROBUSTNESS(chromatogram
                                      
in the method’s robustness range
injections were used to get chromatogram.
ter(10mM ammonium acetate + 0.1%F .A) (changed 
and 33:77) 
-12)
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as 
of 100mcg/ml was 
ROBUSTNESS(chromatogram
   
Table No.15: Robustness
     Injection Olmesartan 
Area(mAU*)
1 42.832
2 39.879
3 41.156
Avg
Std dev
%RSD
-13)
Medoximil Cilnidipine
%Area Assay Area(mAU*) %Area
52.56 98.22 32.879 47.45
52.89 98.88 31.427 47.75
52.49 98.80 30.749 48.21
98.63
0.3601
0.36
75
Assay
99.76
100.39
101.36
100.50
0.8059
0.80
76
Table no:16 Robustness
     
Injection Olmesartan Medoximil Cilnidipine
Area(mAU*) %Area Assay Area(mAU*) %Area Assay
1 40.867 53.01 99.06 31.889 47.82 100.35
2 41.778 53.59 100.01 30.478 47.79 100.29
3 41.169 52.94 98.93 31.684 47.59 99.87
Avg
Std dev
%RSD
99.33 100.17
0.589 0.261
0.59 0.26
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RESULTS AND DICCUSSION
An exertion has been made for a simple, accurate and precise method for the estimation of
Olmesartan Medoximil and Cilnidipine in pharmaceutical dosage form by an isocratic RP-HPLC 
method.       
                                                                   
Table No.17:
Table No.18: 
Validation parameters
Observed value
Acceptance criteriaOlmesartan Medoximil Cilnidipine
System suitability
Tailing factor
Theoretical plates (N)
%RSD
1.2
2631
0.03
1.06
3504
0.10
As per USP
NMT 2.5
NLT 1500
NMT 2.0
S.No Drug RT
1.
Olmesartan 
Medoximil
2.467
2. Cilnidipine 4.731
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 At 258nm Olmesartan Medoximil and Cilnidipine were eluted at 2.467min, 4.731min, 
respectively using ammonium acetate in 0.1% Formic acid and Methanol  in the ratio (20:80) 
as mobile phase and a flow rate of 1mL/min.
 Specificity: Olmesartan Medoximil and Cilnidipine were shows no interferences due to othe 
components
 Precision: The % RSD values obtained for peak areas of Olmesartan Medoximil and 
Cilnidipine were in range of 0.30-0.91, which were within the acceptance criteria.
 Ruggedness: The % RSD values obtained for peak areas of Olmesartan Medoximil and 
Cilnidipine were in range of 0.10-0.15, which were within the acceptance criteria.
 Accuracy: The percentage recovery obtained values were in the range of 100.7-100.62%
which were within acceptance criteria.
 Linearity: Correlation coefficient was found to be greater than 0.995.
 Robustness: The % RSD values obtained for peak areas of Olmesartan Medoximil and 
Cilnidipine were in range of 0.91-1.77%, which were within the acceptance criteria.
              
Table No.19: Statistical analysis
S.No Validation parameters Acceptance  criteria
Observed values
1 Precision %RSD≤2 0.30-0.91
2 Accuracy 98%-102% 100.7-100.62%
3 Linearity NLT 0.995 0.995-0.999
4 Robustness %RSD≤2 0.26-0.80
5 Ruggedness %RSD≤2 0.10-0.15
6 Specificity No interferances nil
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SUMMARY AND CONCLUSION
In order to develop a Liquid Chromatographic method effectively, most of the effort should be 
spent in method development and optimization as this will improve the final method 
performance.The method validations documents for its intended purpose.
A fast isocratic HPLC-PDA method was developed for the estimation of Olmesartan Medoximil 
and Olmesartan in tablet dosage form. The total run time was 8 minutes. Simple buffer was used. 
The mobile phases were easy to prepare and economical. 
The baseline with low signal to noise ratio was obtained. Each peak eluted with good resolution and 
no carryover was observed. Since the solutions were stable only for 24 hrs at room temperature. 
The purity of each peak was observed in PDA, from which an inference can be drawn that there is 
no interference of other peaks in the particular peak.
The method allows high samples through put due to short run time. Thus, selective, simple and 
rapid method was developed. 
The method was validated with different analytical performance characteristics and data was 
compiled. The results satisfied the acceptance criteria. This demonstrated that the HPLC method 
developed was specific, linear, accurate, precise and robust.
This work provided me a great opportunity to have an exposure with the instruments used in 
Pharmaceutical Industry. 
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